The full text of this article hosted at is unavailable due to technical difficulties.

Original Paper

Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles

Johan Gabrielsson

Corresponding Author

E-mail address: [email protected]

PK/PD Section, Preclinical Development, AstraZeneca R&D Södertälje, S‐151 85 Södertälje, Sweden

PK/PD Section, Preclinical Development, AstraZeneca R&D Södertälje, S‐151 85 Södertälje, Sweden
Search for more papers by this author
William J. Jusko

Department of Pharmaceutics, School of Pharmacy, 565 Hochstetter Hall, Buffalo, NY 14260, USA

Search for more papers by this author
Liisi Alari

General Pharmacology, Preclinical Development, AstraZeneca R&D Södertälje, S‐151 85 Södertälje, Sweden

Search for more papers by this author
First published: 01 November 2000
Cited by: 36


The most common approach to in vivo pharmacokinetic and pharmacodynamic modeling involves sequential analysis of the plasma concentration versus time and then response versus time data, such that the plasma kinetic model provides an independent function, driving the dynamics. However, response versus time data, even in the absence of measured drug concentrations, inherently contain useful information about the turnover characteristics of response (turnover rate, half‐life of response), the drug's biophase kinetics (F, half‐life) as well as the pharmacodynamic characteristics (potency, intrinsic activity). Previous analyses have assumed linear kinetics, linear dynamics, no time lag between kinetics and dynamics (single‐valued response), and time constant parameters. However, this report demonstrates that the drug effect can be indirect (antinociception, cortisol/adrenocorticotropin (ACTH), body temperature), display nonlinear kinetics, display back mechanisms (nonstationarity, cortisol/ACTH) and exhibit hysteresis with the drug levels in the biophase (antinociception, body temperature). It is also demonstrated that crucial determinants of the success of modeling dose–response–time data are the dose selection, multiple dosing, and to some extent different input rates and routes. This report exemplifies the possibility of assigning kinetic forcing functions in pharmacodynamic modeling in both preclinical and clinical studies for the purpose of characterizing (discrimination between turnover and drug‐specific parameters) response data and optimizing subsequent clinical protocols, and for identification of inter‐individual differences. Copyright © 2000 John Wiley & Sons, Ltd.

Number of times cited according to CrossRef: 36

  • , Model‐Based Meta‐Analysis Use in the Development of Therapeutic Proteins, Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune‐Mediated Inflammatory Diseases, (93-124), (2019).
  • , Modelling the dose–response relationship: the fair share of pharmacokinetic and pharmacodynamic information, British Journal of Clinical Pharmacology, 83, 6, (1240-1251), (2017).
  • , Nonclassical Pharmacodynamics, Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics, 10.1007/978-3-319-27598-7_13, (361-403), (2016).
  • , Dose–response-time modelling: Second-generation turnover model with integral back control, European Journal of Pharmaceutical Sciences, 81, (189), (2016).
  • , Analysis of clinical trials with biologics using dose–time‐response models, Statistics in Medicine, 34, 22, (3017-3028), (2015).
  • , Challenges in Pharmacology Modelling, Journal of Dynamics and Differential Equations, 27, 3-4, (941), (2015).
  • , Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice, Journal of Pharmacokinetics and Pharmacodynamics, 42, 6, (709), (2015).
  • , Modeling Perfusion Dynamics in the Skin During Iontophoresis of Vasoactive Drugs Using Single‐Pulse and Multiple‐Pulse Protocols, Microcirculation, 22, 6, (446-453), (2015).
  • , A semi-mechanistic model of bone mineral density and bone turnover based on a circular model of bone remodeling, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-015-9423-3, 42, 4, (315-332), (2015).
  • , Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD), Pharmaceutical Research, 32, 2, (617), (2015).
  • , Optimal design of clinical trials with biologics using dose‐time‐response models, Statistics in Medicine, 33, 30, (5249-5264), (2014).
  • , Dose–response–time data analysis involving nonlinear dynamics, back and delay, European Journal of Pharmaceutical Sciences, 59, (36), (2014).
  • , Romiplostim dose–response in patients with myelodysplastic syndromes, British Journal of Clinical Pharmacology, 75, 6, (1445-1454), (2013).
  • , Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values, Pharmaceutical Research, 29, 9, (2628), (2012).
  • , Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose‐Insulin Model, The Journal of Clinical Pharmacology, 52, 12, (1861-1871), (2013).
  • , Demonstrating bioequivalence using clinical endpoint studies, Journal of Veterinary Pharmacology and Therapeutics, 35, s1, (31-37), (2012).
  • , Romiplostim Dose Response in Patients With Immune Thrombocytopenia, The Journal of Clinical Pharmacology, 52, 10, (1540), (2012).
  • , Modeling and Simulation in the Development of Cardiovascular Agents, Clinical Trial Simulations, 10.1007/978-1-4419-7415-0_10, (199-226), (2010).
  • , Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients, Journal of Pharmacokinetics and Pharmacodynamics, 38, 1, (105), (2011).
  • , A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age, Clinical Pharmacology & Therapeutics, 87, 6, (727-734), (2010).
  • , Intravenous morphine titration in immediate postoperative pain management: Population kinetic–pharmacodynamic and logistic regression analysis, Pain, 144, 1, (139), (2009).
  • , Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations, Drug Discovery Today, 14, 7-8, (358), (2009).
  • , Pharmacokinetic and Pharmacodynamic Modeling of a Monoclonal Antibody Antagonist of Glucagon Receptor in Male ob/ob Mice, The AAPS Journal, 10.1208/s12248-009-9150-z, 11, 4, (700-709), (2009).
  • , PHARMACODYNAMICS, Pharmacology and Therapeutics, 10.1016/B978-1-4160-3291-5.50018-4, (203-218), (2009).
  • , Semi-Mechanistic Model for Neutropenia after High Dose of Chemotherapy in Breast Cancer Patients, Pharmaceutical Research, 10.1007/s11095-009-9910-6, 26, 8, (1952-1962), (2009).
  • , Evaluation of drugs in pediatrics using K‐PD models: perspectives, Fundamental & Clinical Pharmacology, 22, 6, (589-594), (2008).
  • , Pharmacokinetic‐pharmacodynamic modelling of S(−)‐atenolol in rats: reduction of isoprenaline‐induced tachycardia as a continuous pharmacodynamic endpoint, British Journal of Pharmacology, 151, 3, (356-366), (2009).
  • , Modelling Response Time Profiles in the Absence of Drug Concentrations: Definition and Performance Evaluation of the K–PD Model, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-006-9035-z, 34, 1, (57-85), (2006).
  • , Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development, Clinical Pharmacokinetics, 10.2165/00003088-200746090-00001, 46, 9, (713-737), (2007).
  • , Pharmacokinetic/Pharmacodynamic Feedback Modelling of the Functional Corticosterone Response in Rats after Acute Treatment with Escitalopram, Basic & Clinical Pharmacology & Toxicology, 100, 3, (182-189), (2007).
  • , An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers, British Journal of Clinical Pharmacology, 64, 2, (125-132), (2007).
  • , Pharmacokinetics/Pharmacodynamics of Bisphosphonates, Clinical Pharmacokinetics, 44, 6, (551), (2005).
  • , The effect of formoterol over 24h in patients with asthma: the role of enantiomers, Pulmonary Pharmacology & Therapeutics, 18, 2, (109), (2005).
  • , Inferring Half-Lives at the Effect Site of Oligonucleotide Drugs, Nucleic Acid Therapeutics, 10.1089/nat.2018.0739, (2018).
  • , Revisiting the Pharmacology of Unfractionated Heparin, Clinical Pharmacokinetics, 10.1007/s40262-019-00751-7, (2019).